Dr. Ozeri Galai brings 15 years of experience in human genetics and CF. Since company establishment, Ozeri-Galai has led the research of SpliSense projects in the field of ASO-based therapies, including the discovery of new targets in pulmonary diseases, screening for leading drug candidates and preclinical development.
Dr. Ozeri Galai was a research fellow in the Genetics Department at the Hebrew University. She holds a PhD in genetics and an MBA in finance from the Hebrew University.